Current Report Filing (8-k)
February 18 2022 - 4:06PM
Edgar (US Regulatory)
0001094038
false
0001094038
2022-02-16
2022-02-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
February 16, 2022
Date of Report (Date of earliest event reported)
MARKER THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
001-37939 |
45-4497941 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
3200 Southwest Freeway
Suite 2500
Houston, Texas |
|
77027 |
(Address of principal executive offices) |
|
(Zip Code) |
(713) 400-6400
Registrant’s telephone number, including
area code
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
MRKR |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 3.01 | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On February 16, 2022, Marker Therapeutics, Inc.
(the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the
Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock
has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on
the listing or trading of the Company’s common stock on The Nasdaq Global Market.
The Company has 180 calendar days, or until August
15, 2022, to regain compliance with the minimum bid price requirement. To regain compliance, the minimum bid price of the Company’s
common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-calendar day
grace period. In the event the Company does not regain compliance with the minimum bid price requirement by August 15, 2022, the Company
may be eligible for an additional 180-calendar day compliance period if it elects to transfer to The Nasdaq Capital Market to take advantage
of the additional compliance period offered on that market. To qualify, the Company would be required to meet the continued listing requirement
for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of
the bid price requirement, and would need to provide written notice of its intention to cure the bid price deficiency during the second
compliance period. The Company’s failure to regain compliance during this period could result in delisting.
The Company intends to actively monitor the bid
price of its common stock and will consider available options to regain compliance with the listing requirements. There can be no assurance
that the Company will be able to regain compliance with Nasdaq’s Listing Rule 5450(a)(1) or will otherwise be in compliance with
other Nasdaq listing criteria.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Marker Therapeutics, Inc. |
|
|
|
Dated: February 18, 2022 |
By: |
/s/ Anthony Kim |
|
|
Anthony Kim |
|
|
Chief Financial Officer |
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024